1. CAR T relapse DLBCL patients is something like 3,000 patients per annum (US)
2. Drugs are priced relative to QALY not incidence rates
3. You have applied EPS incorrectly. Earnings per share is applied to income (revenue minus costs) not revenue.
4. Similarly, you've applied P/E ratio incorrectly to revenue and instead it should be to earnings (net income).
5. Using the dollar value for market size and then claiming 10% market capture is incorrect due to differential pricing within that market.
You need to clearly define the patient population, use similar drugs to price, and apply discount rates, probability of success, and costs to future revenues. If you do all of this, you will quickly determine that there is very little upside for IMUs programs.
IMU Price at posting:
4.1¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)